Company: IMRX
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001790340-25-000061
Chunk: 503

Company: Immuneering Corp
Filing Date: 2025-05-05
Form: 10-Q
Item: Part I, Item 2
Chunk 503
---
%

Research and development expenses increased by approximately $0.3 million, or 2.4%, to approximately $11.5 million for the three months ended March 31, 2025 as compared to approximately $11.2 million for the three months ended March 31, 2024. The increase of approximately $0.3 million was primarily due to an increase of approximately $0.4 million related to direct research and development expenses, including a $0.6 million increase in expenses related to IMM-1-104 and a $0.6 million increase in expenses related to IMM-6-415, offset by decreased preclinical spend of approximately $0.8 million due to the Company's prioritization of IMM-1-104. The remaining variance was driven by a decrease in unallocated research and development expenses of approximately $0.1 million, which was primarily driven by decreased employee-related costs (including due to a lower employee headcount) of $0.3 million, offset by increased stock-based compensation costs of $0.2 million, in addition to facilities and other expenses of $22 thousand.

27

General and Administrative

The following table summarizes the components of our general and administrative expenses for the periods indicated:

Three Months Ended March 31,Change20252024$% (in thousands, except percentages)Employee-related costs$2,156 $2,188 $(32)(1.5)%Stock-based compensation expense959 908 51 5.6 %Professional fees629 630 (1)(0.2)%Facilities and other allocated expenses59 95 (36)(37.9)%Other203 295 (92)(31.2)%Total general and administrative$4,006 $4,116 $(110)(2.7)%

General and administrative expenses decreased by approximately $0.1 million, or 2.7%, to approximately $4.0 million for the three months ended March 31, 2025 compared to approximately $4.1 million for the three months ended March 31, 2024. The decrease of approximately $0.1 million was primarily due to a decrease in employee-related costs of $0.1 million, in addition to a $0.1 million decrease in professional fees for accounting, auditing and legal services and facilities and other allocated expenses, in the aggregate, offset by increased stock-based compensation expense of approximately $0.1 million.

Amortization of Intangible Asset

Amortization